[go: up one dir, main page]

ES2114687T3 - Formulacion inmunogena a base de antigenos ospc, destinada para la prevencion y para el tratamiento de la enfermedad de lyme y procedimientos de recombinacion para la preparacion de estos antigenos. - Google Patents

Formulacion inmunogena a base de antigenos ospc, destinada para la prevencion y para el tratamiento de la enfermedad de lyme y procedimientos de recombinacion para la preparacion de estos antigenos.

Info

Publication number
ES2114687T3
ES2114687T3 ES94915562T ES94915562T ES2114687T3 ES 2114687 T3 ES2114687 T3 ES 2114687T3 ES 94915562 T ES94915562 T ES 94915562T ES 94915562 T ES94915562 T ES 94915562T ES 2114687 T3 ES2114687 T3 ES 2114687T3
Authority
ES
Spain
Prior art keywords
antigens
ospc
prevention
preparation
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94915562T
Other languages
English (en)
Inventor
Ian Livey
Brian Crowe
Friedrich Dorner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno AG filed Critical Immuno AG
Application granted granted Critical
Publication of ES2114687T3 publication Critical patent/ES2114687T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

UN ENFOQUE EN LA FORMULACION DE VACUNA BORRELIA, TOMANDO EN CUENTA LA INFORMACION SEROLOGICA, GENOTIPICA Y EPIDEMIOLOGICA POR LA QUE LAS PROTEINAS OSPC DE DIFERENTES RAMIFICACIONES DE B. BURGDORFERI SON AGRUPADOS ENTRE SI. LOS ANTIGENOS OSPC SON ELEGIDOS PARA CONSTITUIR UNA MUESTRA REPRESENTATIVA DE TALES GRUPOS, DE MANERA QUE LA VACUNA RESULTANTE PROPORCIONA LA MAYOR PROTECCION CRUZADA CON EL MENOR NUMERO DE ANTIGENOS.
ES94915562T 1993-04-29 1994-04-29 Formulacion inmunogena a base de antigenos ospc, destinada para la prevencion y para el tratamiento de la enfermedad de lyme y procedimientos de recombinacion para la preparacion de estos antigenos. Expired - Lifetime ES2114687T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5386393A 1993-04-29 1993-04-29

Publications (1)

Publication Number Publication Date
ES2114687T3 true ES2114687T3 (es) 1998-06-01

Family

ID=21987063

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94915562T Expired - Lifetime ES2114687T3 (es) 1993-04-29 1994-04-29 Formulacion inmunogena a base de antigenos ospc, destinada para la prevencion y para el tratamiento de la enfermedad de lyme y procedimientos de recombinacion para la preparacion de estos antigenos.

Country Status (16)

Country Link
EP (1) EP0701612B1 (es)
JP (1) JPH08509371A (es)
AT (1) ATE162550T1 (es)
AU (1) AU683260B2 (es)
CA (1) CA2161534A1 (es)
CZ (1) CZ289212B6 (es)
DE (1) DE69408135T2 (es)
DK (1) DK0701612T3 (es)
ES (1) ES2114687T3 (es)
FI (1) FI955150A (es)
HR (1) HRP940279B1 (es)
HU (1) HU217024B (es)
NO (1) NO954318L (es)
PL (1) PL178775B1 (es)
SK (1) SK279968B6 (es)
WO (1) WO1994025596A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5915049A (en) * 1992-02-25 1999-06-22 Pfu Limited Binarization system for an image scanner
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6716574B2 (en) 1996-05-02 2004-04-06 Dako A/S Osp-C derived peptide fragments
EP0896583B1 (en) * 1996-05-02 2003-02-05 Dako A/S Use of peptide fragments derived from osp-c for diagnostic methods
US5846946A (en) * 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
AT405940B (de) * 1996-06-21 1999-12-27 Immuno Ag Verfahren zur gewinnung und reinigung von rekombinantem, nicht-lipidiertem osp-protein
DE19629543C2 (de) * 1996-07-22 1999-02-11 Immuno Ag Immunassay zum Nachweis von anti-B. burgdorferi Antikörpern und Verfahren zur Serodiagnose bei Lyme Borreliose, diagnostische Mittel und Testkits zur Durchführung der Verfahren
DE19740735A1 (de) 1997-09-16 1999-03-18 Max Planck Gesellschaft Arzneimittel zur Therapie einer manifesten Lyme-Borreliose
DE69938183T2 (de) 1998-07-31 2009-02-19 Gundersen Lutheran Medical Foundation, Inc., La Crosse Verwendungen eines borreliaziden epitops des aussermembranproteins c von borrelia burgdorferi (ospc) als impstoff
DK1194559T3 (da) 1999-06-18 2007-02-05 Univ New York State Res Found Grupper af Borrelia burgdorferi, som forårsager Lyme sygdom hos mennesker
AU2001285049A1 (en) 2000-08-18 2002-03-04 Brookhaven Sciences Associates, Llc Altered ospa of borrelia burgdorferi
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
EP1957520A4 (en) * 2005-11-29 2009-05-27 Univ Virginia Commonwealth POLYVALENTIC CHIMERIC OSPC VACCINOGEN AND DIAGNOSTIC ANTIGEN
CN101573135B (zh) * 2006-11-03 2013-06-12 先灵-普劳有限公司 犬莱姆病疫苗
CZ301244B6 (cs) * 2007-11-14 2009-12-16 Bioveta, A.S. Univerzální vakcína k lécbe a prevenci Lymeské borreliózy pro humánní a veterinární použití a zpusob její výroby
CZ301548B6 (cs) * 2008-08-20 2010-04-14 Bittner@Libor Univerzální preparát ke zvýšení obranyschopnosti, prevenci, profylaxi a lécbe Lymeské boreliózy pro humánní a veterinární použití, zpusob jeho výroby a použití
WO2025015077A1 (en) * 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease

Also Published As

Publication number Publication date
PL178775B1 (pl) 2000-06-30
NO954318D0 (no) 1995-10-27
DE69408135D1 (de) 1998-02-26
FI955150A0 (fi) 1995-10-27
HU217024B (hu) 1999-11-29
AU6722994A (en) 1994-11-21
CA2161534A1 (en) 1994-11-10
HU9502002D0 (en) 1995-08-28
EP0701612A1 (en) 1996-03-20
DE69408135T2 (de) 1998-06-10
CZ283995A3 (en) 1996-03-13
HRP940279B1 (en) 2000-12-31
SK134195A3 (en) 1996-05-08
JPH08509371A (ja) 1996-10-08
EP0701612B1 (en) 1998-01-21
AU683260B2 (en) 1997-11-06
HRP940279A2 (en) 1997-10-31
PL311301A1 (en) 1996-02-05
SK279968B6 (sk) 1999-06-11
DK0701612T3 (da) 1998-09-21
CZ289212B6 (cs) 2001-12-12
NO954318L (no) 1995-12-29
ATE162550T1 (de) 1998-02-15
FI955150A (fi) 1995-12-28
HUT72923A (en) 1996-06-28
WO1994025596A3 (en) 1994-12-22
WO1994025596A2 (en) 1994-11-10

Similar Documents

Publication Publication Date Title
ES2114687T3 (es) Formulacion inmunogena a base de antigenos ospc, destinada para la prevencion y para el tratamiento de la enfermedad de lyme y procedimientos de recombinacion para la preparacion de estos antigenos.
DK0598816T3 (da) Osp A-proteiner fra Borrelia Burgdorferi-undergrupper, hvilke proteiner koder for gener og vacciner
FI904597A0 (fi) Vaccin mot lyme-sjukdom.
AR003125A1 (es) Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la
BR9305711A (pt) Vacina à base de urease contra infecção por helicobacter
NO913722D0 (no) Vaksinasjon og fremgangsmaater mot sykdommer som foelge av patogene responser fra spesifikke t-cellepopulasjoner.
YU134484A (en) Process for making oral imunogenic compositions
NO975620D0 (no) Immunologiske kombinasjonssammensetninger og fremgangsmåter
EP0299438A3 (en) Heat shrinkable envelope and process for its manufacture
DE60030859D1 (de) Gruppen von borrelia burgdorferi, die lyme krankheit verursachen
ATE76548T1 (de) Verfahren und vorrichtung zur erzeugung von stereoskopischen bildern.
MX167117B (es) Topologia de red en anillo de fibras opticas
ES2134197T3 (es) Vacunas contra el virus del herpes simplex vp16.
ES2096323T3 (es) Un rompecabezas.
EP0716613A4 (en) TREATING A GASTRODUODENAL DISEASE CAUSED BY -i (HELICOBAKTER PYLORI)
AR001618A1 (es) Adyuvante de saponina del arbol quillajay y formulacion de vacuna que contiene el mismo
DE69122240D1 (de) Antigen-wirkende proteine von borrelia burgdorferi
BR0315980A (pt) Antìgenos p153 e p156 para o diagnóstico imunológico da ehrlichiose canina e humana e uso dos mesmos
ES2061603T3 (es) Mutantes viricos de la rinotraqueitis bovina infecciosa, vacunas que los contienen, metodos para la produccion de los mismos y metodos para el empleo de los mismos.
Pavia et al. The major epidemiologic, microbiologic, immunologic, and clinical aspects of Lyme disease that form the basis for a newly developed vaccine that may become available soon for human use
ATE329615T1 (de) Borrelia burgdorferi bacterin
ES2146013T3 (es) Champues suaves para el cabello.
ES2084987T3 (es) Aparato para fabricar postes conificados de uso industrial, para alumbrado y aplicaciones similares.
ES2108614B1 (es) Vacunas polimerizadas.
ES2058240T3 (es) Nuevos peptidos sinteticos inmunologicamente activos utiles para la preparacion de una vacuna antimalarica.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 701612

Country of ref document: ES